Skip to content

DiBiRA

Digital biomarkers in patients with rheumatoid arthritis - DiBiRA

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57984
Enrollment
30
Registered
2025-07-31
Start date
2025-06-06
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis Rheumatoid Arthritis

Interventions

Participants will wear two medical-grade wearables:Corsano CardioWatch (30 days)McRoberts MoveMonitor (14 days) They will also complete short questionnaires via an app and on paper.

Sponsors

Medisch Spectrum Twente (MST)
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Diagnosis RAAge 18 years or aboveHigh disease activity (DAS28-CRP>4.0)Indication for Triamcinolonacetonide injection (80mg/120 mg, intramusculair)Having a smartphone and willing to installate the Corsano and SEMA3 app

Exclusion criteria

Exclusion criteria: Current or recent treatment with corticosteroids <6 weeks agoContra-indication triamcinolon 80 mg/120 mgConcomitant musculoskeletal or autoimmune diseases other than RA Patients who work night shifts or have other reasons for being awake at nightCardiac implantable devicesComorbidities interfering with HRV parameters and ECG analysis

Design outcomes

Primary

MeasureTime frame
Digital biomarkers: heart rate, ECG, oxygen saturation, breathing rate, temperature, activity, sleep, gait 

Secondary

MeasureTime frame
Disease activity: DAS28-CRP score and patient questionnaires (RAPID3/HAQ2)

Countries

Netherlands

Contacts

Public ContactH.E. Vonkeman

Medisch Spectrum Twente (MST)

research.reumatologie@mst.nl053-4872450

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 11, 2026